Key facts
- Evidium’s last known valuation is $52.7M (Nov 2025).
- It has raised $33.2M; the latest was Later Stage VC ($22.0M) in Nov 2025.
- Notable investors include SeedFolio, Sage Hill Investors, Interwoven Ventures, United Healthcare Services, Hammer Ventures — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Evidium
- ·The full record, as it builds
Funding rounds
No funding rounds for Evidium are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Evidium
Developer of a clinical intelligence platform designed to make medical knowledge computational and transparent for data-driven healthcare. The company offers precision tools that integrate clinical and financial data to connect care and coverage, enabling healthcare providers and payors to predict patient trajectories and costs, improve clinical outcomes, and support informed decision-making.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2020
- Employees
- 31
- Website
- evidium.com/
- Ownership
- Privately Held (backing)
Evidium doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Evidium shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Evidium in its N-PORT filings yet. We sweep new filings monthly.